Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Study finds top AI models still struggle with clinical reasoning

14

Apr 2026

Study finds top AI models still struggle with clinical reasoning

Researchers tested 21 frontier large language models on 29 stepwise MSD Manual clinical vignettes and found that, although many models performed well on final diagnosis, they remained much weaker at differential diagnosis and diagnostic testing. They also introduced the PrIME-LLM score, a multidimensional benchmark designed to better capture balanced clinical reasoning across the full workflow rather than raw accuracy alone.

Alzheimer's risk gene APOE4 impacts bone health in females

13

Apr 2026

Alzheimer's risk gene APOE4 impacts bone health in females

Scientists at the Buck Institute for Research on Aging, along with collaborators at UC San Francisco, have discovered that APOE4, the most common genetic risk factor for Alzheimer's disease, causes bone quality deficits specifically in female mice, through a mechanism that is invisible to standard imaging and can emerge as early as midlife.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.